Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab

Alfredo Pece, Claudio Azzolini, Maurizio Battaglia Parodi, Ferdinando Bottoni, Paola Danzi, Simone Donati, Ugo Introini, Vincenzo Pucci, Francesco Semeraro, Francesco Viola

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) is an irreversible pathology that is the principal cause of serious loss of central vision and legal blindness among people over 60 years of age. There are two forms of AMD: the dry, or atrophic form, and the wet, neovascular form. The latter is less frequent but is the cause of approximately 80-90% of cases of serious loss of vision in a short time period. Early diagnosis is therefore essential to permit intervention as promptly as possible. Currently, the most effective therapy for neovascular AMD uses the new class of anti-VEGF drugs, and ranibizumab is todays 'gold standard for this treatment. The Progetto LUCE (LUCE Project) consists of an advisory board of retinal disease specialists in Lombardy, Italy, whose task is to propose a consensus for the diagnosis, treatment and follow-up of neovascular AMD patients treated with ranibizumab on the basis of a review of the scientific evidence and Italian national health service regulations and the clinical experience of the advisory board members.

Original languageEnglish
Pages (from-to)219-225
Number of pages7
JournalExpert Review of Ophthalmology
Volume7
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Macular Degeneration
Consensus
Pathology
Health
Retinal Diseases
National Health Programs
Blindness
Therapeutics
Italy
Vascular Endothelial Growth Factor A
Early Diagnosis
Ranibizumab
Pharmaceutical Preparations

Keywords

  • age-related macular degeneration
  • anti-VEGF
  • monitoring
  • neovascularization
  • ranibizumab
  • treatment

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. / Pece, Alfredo; Azzolini, Claudio; Parodi, Maurizio Battaglia; Bottoni, Ferdinando; Danzi, Paola; Donati, Simone; Introini, Ugo; Pucci, Vincenzo; Semeraro, Francesco; Viola, Francesco.

In: Expert Review of Ophthalmology, Vol. 7, No. 3, 06.2012, p. 219-225.

Research output: Contribution to journalArticle

Pece, Alfredo ; Azzolini, Claudio ; Parodi, Maurizio Battaglia ; Bottoni, Ferdinando ; Danzi, Paola ; Donati, Simone ; Introini, Ugo ; Pucci, Vincenzo ; Semeraro, Francesco ; Viola, Francesco. / Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. In: Expert Review of Ophthalmology. 2012 ; Vol. 7, No. 3. pp. 219-225.
@article{e7f4ea0645f94e4abfce201c8bb0b281,
title = "Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab",
abstract = "Age-related macular degeneration (AMD) is an irreversible pathology that is the principal cause of serious loss of central vision and legal blindness among people over 60 years of age. There are two forms of AMD: the dry, or atrophic form, and the wet, neovascular form. The latter is less frequent but is the cause of approximately 80-90{\%} of cases of serious loss of vision in a short time period. Early diagnosis is therefore essential to permit intervention as promptly as possible. Currently, the most effective therapy for neovascular AMD uses the new class of anti-VEGF drugs, and ranibizumab is todays 'gold standard for this treatment. The Progetto LUCE (LUCE Project) consists of an advisory board of retinal disease specialists in Lombardy, Italy, whose task is to propose a consensus for the diagnosis, treatment and follow-up of neovascular AMD patients treated with ranibizumab on the basis of a review of the scientific evidence and Italian national health service regulations and the clinical experience of the advisory board members.",
keywords = "age-related macular degeneration, anti-VEGF, monitoring, neovascularization, ranibizumab, treatment",
author = "Alfredo Pece and Claudio Azzolini and Parodi, {Maurizio Battaglia} and Ferdinando Bottoni and Paola Danzi and Simone Donati and Ugo Introini and Vincenzo Pucci and Francesco Semeraro and Francesco Viola",
year = "2012",
month = "6",
doi = "10.1586/eop.12.24",
language = "English",
volume = "7",
pages = "219--225",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab

AU - Pece, Alfredo

AU - Azzolini, Claudio

AU - Parodi, Maurizio Battaglia

AU - Bottoni, Ferdinando

AU - Danzi, Paola

AU - Donati, Simone

AU - Introini, Ugo

AU - Pucci, Vincenzo

AU - Semeraro, Francesco

AU - Viola, Francesco

PY - 2012/6

Y1 - 2012/6

N2 - Age-related macular degeneration (AMD) is an irreversible pathology that is the principal cause of serious loss of central vision and legal blindness among people over 60 years of age. There are two forms of AMD: the dry, or atrophic form, and the wet, neovascular form. The latter is less frequent but is the cause of approximately 80-90% of cases of serious loss of vision in a short time period. Early diagnosis is therefore essential to permit intervention as promptly as possible. Currently, the most effective therapy for neovascular AMD uses the new class of anti-VEGF drugs, and ranibizumab is todays 'gold standard for this treatment. The Progetto LUCE (LUCE Project) consists of an advisory board of retinal disease specialists in Lombardy, Italy, whose task is to propose a consensus for the diagnosis, treatment and follow-up of neovascular AMD patients treated with ranibizumab on the basis of a review of the scientific evidence and Italian national health service regulations and the clinical experience of the advisory board members.

AB - Age-related macular degeneration (AMD) is an irreversible pathology that is the principal cause of serious loss of central vision and legal blindness among people over 60 years of age. There are two forms of AMD: the dry, or atrophic form, and the wet, neovascular form. The latter is less frequent but is the cause of approximately 80-90% of cases of serious loss of vision in a short time period. Early diagnosis is therefore essential to permit intervention as promptly as possible. Currently, the most effective therapy for neovascular AMD uses the new class of anti-VEGF drugs, and ranibizumab is todays 'gold standard for this treatment. The Progetto LUCE (LUCE Project) consists of an advisory board of retinal disease specialists in Lombardy, Italy, whose task is to propose a consensus for the diagnosis, treatment and follow-up of neovascular AMD patients treated with ranibizumab on the basis of a review of the scientific evidence and Italian national health service regulations and the clinical experience of the advisory board members.

KW - age-related macular degeneration

KW - anti-VEGF

KW - monitoring

KW - neovascularization

KW - ranibizumab

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84861731047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861731047&partnerID=8YFLogxK

U2 - 10.1586/eop.12.24

DO - 10.1586/eop.12.24

M3 - Article

AN - SCOPUS:84861731047

VL - 7

SP - 219

EP - 225

JO - Expert Review of Ophthalmology

JF - Expert Review of Ophthalmology

SN - 1746-9899

IS - 3

ER -